Spyre Therapeutics分享了二期溃疡性结肠炎试验的积极结果。 Spyre Therapeutics shares surge on positive Phase 2 ulcerative colitis trial results.

斯派尔疗法公司的股价在周一升, 因为该公司报告了其性结肠炎药物SPY001的第二阶段试验结果呈阳性的报道. Spyre Therapeutics shares surged Monday after the company reported positive Phase 2 trial results for its ulcerative colitis drug SPY001. 治疗显示疾病活动显著减少,并达到其主要有效性目标,表明作为这种病症的新疗法具有很强的潜力. The treatment showed a significant reduction in disease activity and met its primary effectiveness goals, signaling strong potential as a new therapy for the condition.